Navigation Links
Cephalon General Counsel John E. Osborn to Resign Position
Date:2/8/2008

vailable at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
2. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
3. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
5. Cephalon Submits Supplemental New Drug Application for FENTORA
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Quarterly Conference Call Invitation
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
10. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Eckert & Ziegler Vitalea Science (EZVS), a leading ... pharmaceutical and biotech industry, has announced that Dr. Mark ... of Director of Science & Technology. , “Mark brings ... drug metabolism and bioanalysis to EZVS in both pharma ...
(Date:1/22/2015)... CAMBRIDGE, Mass (PRWEB) January 21, 2015 Cambridge ... Semantic Web technology, today announced that 2014 was a record-breaking ... expanding the capabilities of the Anzo Smart Data Platform and ... discover and utilize insights from diverse data which led to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 zFlo Motion ... pleased to announce an exciting product from a new partner. ... analysis solutions over the past 15 years, with offerings in ... recently, their 3D IMU system (inertial measurement unit), iSen, is ...
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... "Quantum Man: Richard Feynman,s Life in Science," ASU Foundation Professor and ... a legendary and sometimes very public modern physicist, has been chosen ... in the UK. Feynman is one of the most ... he did much to bring science to the people, taking time ...
... Technologies, a global provider of comprehensive scientific management solutions, ... industry, is pleased to announce the company has donated ... Susan G. Komen for the Cure ® Tissue ... donation was presented to the Komen Tissue Bank on ...
... Dec. 21, 2011 Acumen Pharmaceuticals announces today ... (formerly Merck & Co., Inc.) of a 2003 ... Merck exclusive worldwide rights to develop and commercialize ... Merck,s decision to discontinue this ...
Cached Biology Technology:Book on Richard Feynman nets honors for Arizona State professor 2Book on Richard Feynman nets honors for Arizona State professor 3BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research 2BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research 3Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer's Disease From Merck 2
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced the ... report to their offering. ... in this market is the increasing demand for medical ... of patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... addition of the "Biometrics Market in India 2015-2019" ... major trend emerging in this market is the adoption ... than one characteristic of an individual for verification and ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Institutes of Health (NIH) awarded Benaroya Research Institute at Virginia ... the human genome which can explain why some white blood ... multiple sclerosis (MS). This is the first study to look ... responsible for the devastation caused by MS. The broad-based study ...
... (Sept. 3, 2013) Clay, an abundant and cheap natural ... operate at very high temperatures, according to Rice University researchers ... of materials scientist Pulickel Ajayan reported today in Nature,s online ... at temperatures of up to 200 degrees Celsius (392 degrees ...
... Mass grave detection . . . ... gain closure, and killers may receive appropriate punishment, because ... graves. While investigators can find some graves, perhaps hundreds ... Tennessee,s Forensic Anthropology Center and Oak Ridge National Laboratory ...
Cached Biology News:First study to investigate the human genome in multiple sclerosis 2Clay key to high-temperature supercapacitors 2Clay key to high-temperature supercapacitors 3September 2013 story tips 2September 2013 story tips 3
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
... tetrasodium bromide), 50mg/vial. MTT is a pale ... cells to yield a dark blue formazan ... even freshly dead cells do not cleave ... a component of Chemicons MTT assay kit, ...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
Determin interaction of your protein with Echelons lipids...
Biology Products: